资讯

Yahoo Finance15 天
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
Ractigen’s small activating RNA (saRNA) therapy, RAG-01, designed to treat non-muscle invasive bladder cancer (NMIBC) has shown early promise in a Phase I trial. Data presented at the European ...
clinicaltrialsarena15 天
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
Credit: Shutterstock / Shidlovski Ractigen’s small activating RNA (saRNA) therapy, RAG-01, designed to treat non-muscle invasive bladder cancer (NMIBC) has shown early promise in a Phase I trial. Data ...
PipelineReview.com16 天
Ractigen’s RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data ...
NANTONG, China and MELBOURNE, Australia I March 24, 2025 I Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today announced the ...
Fox 44 Waco News16 天
Ractigen's RAG-01 Shows Promising Early Complete Responses in Phase I NMIBC Trial, Data ...
NANTONG, China and MELBOURNE, Australia, March 24, 2025 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage biopharmaceutical company pioneering small activating RNA (saRNA) therapeutics, today ...